Hybrid immunity and host factors: implications on serostatus induced by COVID-19 vaccines
Microbes, Infection and Chemotherapy · 14.07.2025 · 5 · e2420
DOI: 10.54034/mic.e2420 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbes, Infection and Chemotherapy, online erschienen am 14.07.2025. Verfasst von Franklin E. Torres-Jiménez und 8 weiteren Autor:innen. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Monitoring the humoral immune response following SARS-CoV-2 vaccination is crucial to understanding long-term protection, especially in the context of hybrid immunity (HI). This study aimed to evaluate anti-S IgG antibody levels in adults with and without prior COVID-19 infection and explore associated host-related factors.
Methods
A cross-sectional study was conducted in 102 adults from Colombia, grouped by infection history: Group A (with prior COVID-19) and Group B (without prior COVID-19). Anti-S IgG levels were quantified using chemiluminescent immunoassay. Sociodemographic, clinical, and vaccination data were collected via survey. Statistical comparisons were performed using t-tests, Mann–Whitney U tests, and linear regression analysis.
Results
All participants exhibited seropositivity (100%) for anti-S IgG, with high titers persisting up to 23 months post-booster. No significant differences in antibody concentrations were found between groups (p = 0.830). Variables such as sex, age, comorbidities, and type of vaccine did not significantly influence antibody levels. A moderate, significant correlation was found between the number of booster doses and antibody titers in Group A (ρ = 0.453; p = 0.001), but not in Group B. Regression analysis predicted progressively higher titers with additional booster doses.
Conclusions
Robust humoral responses were observed regardless of prior infection, indicating effective vaccine-induced immunity in this population. The number of booster doses was a key factor associated with higher antibody titers, particularly in individuals with hybrid immunity. These findings support the value of continued booster campaigns and underline the need for further research into functional immunity.
Zitieren
APA
Torres-Jiménez, F. E., Mendoza-Torres, E., Alcocer-Olaciregui, A. E., Torres-Ferias, M. F., Mendoza-Zapata, D. A., Cantillo-Barrios, M., Echeverría-Bernal, D. J., Varón-Toscano, V., & Pineda-Awadalla, G. P. (2025). Hybrid immunity and host factors: implications on serostatus induced by COVID-19 vaccines. Microbes, Infection and Chemotherapy, 5, e2420. https://doi.org/10.54034/mic.e2420
Vancouver
Torres-Jiménez FE, Mendoza-Torres E, Alcocer-Olaciregui AE, Torres-Ferias MF, Mendoza-Zapata DA, Cantillo-Barrios M, et al. Hybrid immunity and host factors: implications on serostatus induced by COVID-19 vaccines. Microbes, Infection and Chemotherapy. 2025;5:e2420. doi:10.54034/mic.e2420
BibTeX
@article{TorresJimnez2025,
author = {Torres-Jiménez, Franklin E. and Mendoza-Torres, Evelyn and Alcocer-Olaciregui, Adalgisa E. and Torres-Ferias, María F. and Mendoza-Zapata, Daniel A. and Cantillo-Barrios, Mariangel and Echeverría-Bernal, David J. and Varón-Toscano, Valentina and Pineda-Awadalla, Giselle P.},
title = {Hybrid immunity and host factors: implications on serostatus induced by COVID-19 vaccines},
journal = {Microbes, Infection and Chemotherapy},
year = {2025},
volume = {5},
pages = {e2420},
doi = {10.54034/mic.e2420}
}
EUVIMED